ReviewNature reviews. Clinical oncology2020
Histology-agnostic drug development - considering issues beyond the tissue.
Review in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours.Scientific reports · 2022Pooled it
- Guidelines for clinical evaluation of anti-cancer drugs.Cancer science · 2021Guideline
- BRAF mutations and targeted therapy in unclassified pericytic tumors: insights from genetic analysis and clinical response.BMC cancer · 2025Article
- Informing health system planning for biomarker-based treatment: statistical prevalence projections for solid cancers with key pan-tumour biomarkers (dMMR, MSI, high TMB) in Australia to 2042.The Lancet regional health. Western Pacific · 2025Article
- Agnostic Biomarkers in Molecular Pathology.Journal of clinical practice and research · 2025Review
- Pyrazolo[1,5-Molecules (Basel, Switzerland) · 2024Review
- Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.International journal of molecular sciences · 2024Review
- Tumor Copy Number Alteration Burden as a Predictor for Resistance to Immune Checkpoint Blockade across Different Cancer Types.Cancers · 2024Article
- Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial.International journal of clinical oncology · 2024Article
- Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.Acta pharmaceutica Sinica. B · 2024Review
- Article
- Review
- Back to the Bench: Unveiling the Tissue Context is Crucial to Enhance the Efficacy of Agnostic Therapies in Oncology.Targeted oncology · 2023Article
- Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.Current oncology (Toronto, Ont.) · 2023Review
- Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.Current oncology (Toronto, Ont.) · 2023Article
- Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.Cancer biomarkers : section A of Disease markers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With advances in tumour biology and immunology that continue to refine our understanding of cancer, therapies are now being developed to treat cancers on the basis of specific molecular alterations and markers of immune phenotypes that transcend specific tumour histologies. With the landmark approvals of pembrolizumab for the treatment of patients whose tumours have high microsatellite instability and larotrectinib and entrectinib for those harbouring NTRK fusions, a regulatory pathway has been created to facilitate the approval of histology-agnostic indications. Negative results presented in the past few years, however, highlight the intrinsic complexities faced by drug developers pursuing histology-agnostic therapeutic agents. When patient selection and statistical analysis involve multiple potentially heterogeneous histologies, guidance is needed to navigate the challenges posed by trial design. Additionally, as new therapeutic agents are tested and post-approval data become available, the regulatory framework for acting on these data requires further optimization. In this Review, we summarize the development and testing of approved histology-agnostic therapeutic agents and present data on other agents currently under development. Finally, we discuss the challenges intrinsic to histology-agnostic drug development in oncology, including biological, regulatory, design and statistical considerations.
Indexed as
Identifiers
32528101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.